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ABSTRACT 
Headache disorders are among the most common disorders of the nervous system, with 
migraine alone affecting 14% of women and 6% of men worldwide each year. Headache-related 
self-efficacy, or one’s confidence in preventing and managing headache, is particularly important 
for prevention and management of headache disorders and predicts response to behavioral and 
pharmacological treatments. Allodynia, the perception of non-noxious stimuli as painful due to 
central sensitization, compounds headache-related disability and compromises efficacy of 
triptans. Therefore, migraineurs with allodynia may perceive headache treatments as less 
efficacious and thus have reduced perceived headache-related self-efficacy. However, no 
literature to date has explored the relationship between self-efficacy and allodynia and the 
possible mediating role of fear of pain. The present study aimed to explore the relationship 
between allodynia and self-efficacy and whether fear of pain mediated this relationship among a 
non-treatment seeking sample of young adults with migraine. A significant negative relationship 
was observed between allodynia and self-efficacy in migraineurs, however the indirect effect of 
the mediation model was not statistically significant. Results of the present study suggest 
migraineurs with allodynia experience reduced headache-related self-efficacy, which may be an 
important target for behavioral intervention. 
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I. INTRODUCTION 
Headache.  
Headache disorders are among the most common disorders of the nervous system (WHO, 
2016), currently affecting 22.7% of people in the United States (Smitherman, Burch, Sheikh, & 
Loder, 2013). Global prevalence of current headache disorders is 47%, while lifetime prevalence 
is 66% (Stovner et al., 2007). However, men and women are affected differentially. Headache 
disorders affect 27.6% of women and 14.8% of men in the United States, are associated with 
increased use of healthcare services (Smitherman et al.), and are the second highest cause of 
years lost due to disability (YLD) worldwide (Global Burden of Disease Study Collaborators, 
2016). Additionally, people suffering from headache disorders are 2.8 and 2.3 times more likely 
than people without headache to have a comorbid physical or psychiatric diagnosis, respectively 
(Smitherman et al.). Although head pain is the fifth most common reason for emergency room 
hospital visits (Burch, Rizzoli, & Loder, 2018), headache disorders often go under-diagnosed and 
untreated (Stovner et al.), despite their high prevalence and global burden.  
Migraine. 
Headache disorders broadly represent a number of more specific disorders. “Primary” 
headache disorders, or those not attributable to other causes, include migraine, tension-type 
headache (TTH), trigeminal autonomic cephalalgias such as cluster headache, and other primary 
headache disorders (ICHD-3; International Headache Society [IHS], 2018). The focus herein is 
on migraine, as it is the most common disabling primary headache disorder. Migraine is 
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characterized by severe, pulsating pain that is typically experienced on one side of the head and 
may be aggravated by, or cause avoidance of, routine physical activity. Migraine typically lasts 
between 4 and 72 hours if untreated, with attack frequency (days/month with headache) varying 
greatly. Further, migraineurs must experience at least one additional symptom of nausea, 
vomiting, or both photophobia (i.e., sensitivity to normal light levels) and phonophobia (i.e., 
sensitivity to conversational noise levels). A significant minority of individuals with migraine 
sometimes experience aura, or temporary neurological symptoms that typically precede pain 
onset and gradually resolve. Migraine aura symptoms are visual or sensory in nature. Negative 
visual aura symptoms include vision loss; positive visual symptoms include flashing or 
shimmering lights perceived in one or both eyes (Rothrock, 2009). Sensory aura includes 
numbness and tingling across the face and toward the extremities (Rothrock). Migraine is further 
differentiated by frequency of headache attacks: Episodic migraine is characterized by less than 
15 attacks per month, whereas chronic migraine is characterized by 15 or more attacks per 
month.  
Prevalence and Impact. Migraine is a common and disabling condition. In the United 
States, 17.3% of females and 5.3% of males meet criteria for migraine, according to the 
American Migraine Prevalence and Prevention (AMPP) Study, with rates highest among 
individuals aged 30 to 39 years old (Buse et al., 2013). A recent review of United States 
government studies obtained even higher prevalence rates, such that 20.7% of US women and 
9.7% of men suffered from migraine in the past three months (Burch et al., 2018). These higher 
rates are likely attributable to the fact that government surveillance studies rarely employ full 
diagnostic criteria and are thus more liberal in their estimates. Globally, 10% of the world’s 
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population currently suffers from migraine, with a reported 14% lifetime prevalence (Stovner et 
al., 2007).  
Migraine results in severe impairment during and between attacks, contributing to 
absenteeism, reduced productivity at work, and increased healthcare costs (Holroyd, 2010). For 
men and women of all ages worldwide, migraine is the sixth leading cause of years of life lived 
with disability (YLD), and third leading cause for people aged 15-49 years (Steiner, Stover, & 
Vos, 2016). In large part, migraine’s impact on functioning is attributable to the fact that peak 
prevalence is highest in individuals aged 18-44 years (Burch et al., 2018), a time typically 
marked by high productivity, employment, and childrearing. Although many headache disorders 
are disabling, migraine appears to impact individuals’ functioning most severely. Migraineurs 
experience more lost productive time at work or school than individuals with other headache 
diagnoses (Stewart, Wood, & Razzaghi, 2008), and those with chronic migraine are most 
profoundly affected given their high frequency of attacks (Serrano et al., 2013).  
Migraine-related disability often deters individuals from participating in routine 
activities, including household responsibilities, social events, and exercise. Women in particular 
are more likely to report mild to severe migraine-related disability leading to impairment of 
routine activities (Buse et al., 2013). Though migraine alone impacts functioning, comorbid 
psychiatric diagnoses may compound its effects on functioning. Specifically, migraineurs with a 
comorbid psychiatric diagnosis are more frequently admitted to the hospital, dispensed more 
medications, and incur greater healthcare costs than migraineurs without psychiatric comorbidity 
(Lafata et al., 2004). As such, psychiatric conditions serve as moderator variables in the 
relationship between migraine and disability, prompting clinical consideration when migraineurs 
seek health services. 
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Psychiatric Comorbidity. Assessment and consideration of psychiatric comorbidities in 
migraine patients is particularly important for understanding migraine prognosis. Although 
migraine is classified as a neurological disorder, migraine often occurs with psychiatric disorders 
including depression (Breslau, Lipton, Stewart, Schultz, & Welch, 2003; Hamelsky & Lipton, 
2006; Louter et al., 2015; Nicholson, Houle, Rhudy, & Norton, 2007), generalized anxiety 
disorder (GAD), panic disorder (Smitherman, Penzien, & Maizels, 2008), and bipolar spectrum 
disorder (Hamelsky & Lipton).  
Depression and anxiety disorders are the most common comorbid presentations among 
migraineurs (Hamelsky & Lipton, 2006; Smitherman, Penzien, & Rains, 2013), and these 
relationships appear bidirectional in nature. For instance, individuals with a history of depression 
have a three-fold higher risk of migraine onset than those without prior depression, and those 
with migraine demonstrate a five-fold greater risk for onset of major depression than those 
without migraine histories (Breslau et al., 2003). The presence of comorbid psychopathology 
compounds functional impact (Breslau et al.; Tietjen, Herial, Hardgrive, Utley, & White 2007), 
such that depressed migraineurs show poorer response to treatment, decreased satisfaction with 
medical care, and increased hopelessness and disability (Nicholson et al., 2007). Though 
depression is common among migraineurs, similar findings exist for anxiety disorders comorbid 
with migraine. 
Anxiety and stress are commonly reported as migraine triggers, and anxiety disorders, 
such as GAD, may have an even stronger association with migraine than affective disorders 
(Hamelsky & Lipton, 2006; Smitherman et al., 2008). Migraineurs with a comorbid anxiety 
disorder report increased pain intensity and migraine-related disability accompanied by 
decreased quality of life (Nicholson et al., 2007; Seng et al., 2017). Further, they experience 
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more negative affectivity and symptoms of hyperarousal than migraineurs without anxiety 
(Louter et al., 2015). Adding to heightened disability, and thus affecting quality of life, is one’s 
locus of control. External locus of control is one’s perception that an event is due to chance or 
the power of others, while internal locus of control is one’s perception that an event is due to her 
own behaviors or characteristics (Rotter, 1966). Anxiety mediates the relationship between 
internal headache-specific locus of control (HSLC) and migraine-related quality of life (Grinberg 
& Seng, 2017), such that greater HSLC leads to greater anxiety symptoms, which increases 
migraine-related quality of life impairments. Although high internal HSLC typically bolsters 
migraineurs’ problem-solving and self-efficacy, the unexpected results of this study suggest that 
HSLC may prove maladaptive in the absence of an ability to enact behavioral coping strategies 
(Grinberg & Seng), leading to increased anxiety symptoms. Increased anxiety contributes to 
avoidance of both activities and headache triggers and increases physiological reactivity 
(Nicholson et al.). As such, anxiety inhibits migraineurs’ behavioral repertoire for coping with 
migraine, contributing to migraine progression. An important component of behavioral migraine 
treatment thus includes teaching patients methods of coping with anxiety-related migraine 
triggers (e.g., stress, poor sleep, missing meals, menstruation). 
Associated Psychological Variables 
 Self-Efficacy. In addition to psychiatric comorbidity and HSLC, other psychological 
variables influence migraine and migraine-related disability. Self-efficacy is one’s belief that she 
can enact specific behaviors in specific contexts (Bandura, 1977). Specifically, self-efficacy 
includes both efficacy expectations and outcome expectations (Bandura). Efficacy expectations 
include one’s belief that she can appropriately perform a behavior needed to produce an 
outcome. An outcome expectation, then, is one’s assessment of her behavior as capable of 
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producing the specific outcome. Therefore, one can intelligibly understand the correct behavior 
path for producing a desired outcome without believing she is capable of executing the behavior. 
Self-efficacy is paramount to successful behavioral coping strategies (Bandura) and has 
demonstrated utility in predicting response to headache disorders.  
Within headache disorders, self-efficacy includes one’s beliefs in her ability to prevent 
and manage both headache episodes and headache-related disability. Individuals with headache 
who possess high self-efficacy beliefs take appropriate actions to prevent and manage headache 
pain, and thus typically possess an internal locus of control pertaining to headache. However, 
those with an external locus of control often have low self-efficacy pertaining to headache 
management (French et al., 2000), as they believe there is little they can to do self-manage 
headache. Further, French and colleagues found that individuals who use positive psychological 
strategies (e.g., reducing muscle tension, stress management) to prevent and manage headache 
reported higher perceived self-efficacy than those who did not use such strategies. Additionally, 
self-efficacy favorably impacts headache-related disability, headache frequency, and pain 
severity. High self-efficacy is associated with reduced headache-related disability (French, et al.; 
Peck & Smitherman, 2015), headache frequency (Nicholson et al., 2005), and headache severity 
(Peck & Smitherman). Self-efficacy is a unique and significant predictor of headache disability 
beyond severity and locus of control (French et al.), underscoring the importance of 
distinguishing between self-efficacy and locus of control in migraineurs. More specifically, locus 
of control represents one’s beliefs about both internal and external factors that influence 
migraine, whereas self-efficacy represents one’s beliefs in her ability to affect change on internal 
and external factors (French et al.). Further, the effect of pain severity on disability is mediated 
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by one’s self-efficacy beliefs, such that individuals with high self-efficacy are less disabled than 
those with low self-efficacy when controlling for pain severity (Peck & Smitherman). 
 In addition to playing a role in headache prevention and management, self-efficacy is 
implicated in psychological correlates of headache. Though stressful life events are positively 
correlated with headache frequency, self-efficacy moderates this relationship (Marlowe, 1998), 
such that the relationship weakens as self-efficacy increases. This finding suggests that self-
efficacy may act as a partial buffer between experience of stressful events and headache 
frequency. Further, high self-efficacy is inversely associated with depression and anxiety 
symptomatology, somatic symptoms, and use of maladaptive coping strategies after controlling 
for headache severity and chronicity (Martin, Holroyd, & Rokicki, 1993). These findings 
demonstrate the importance of self-efficacy in improving headache-related disability. 
As related to response to treatment, headache-specific self-efficacy improves following 
behavioral interventions for migraine, as would be expected given that efficacious behavioral 
migraine interventions (progressive muscle relaxation, biofeedback, stress and trigger 
management training) focus on teaching patients skills to better self-manage and prevent attacks 
(Rains, Penzien, McCrory, & Gray, 2005). Similarly, migraineurs who receive concurrent 
behavioral and pharmacological treatment show significantly greater improvement in headache 
self-efficacy than those who receive pharmacological treatment alone over a 12-month period 
(Seng & Holroyd, 2010). Importantly, improvement in self-efficacy following treatment is 
associated with greater reductions in post-treatment migraine frequency (Nicholson et al., 2005). 
Nicholson et al. (2007) noted that self-efficacy in migraineurs aids in managing hyperarousal, 
facilitating treatment adherence, and decreasing migraine-related burden on the healthcare 
system, as enhancing self-efficacy promotes individuals’ ability to prevent and cope with 
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migraine and its associated triggers. Approaching and coping with migraine-related stimuli not 
only bolsters self-efficacy but reduces avoidance behaviors typically found in pain patients, and 
growing evidence suggests that progressive exposure to headache triggers may reduce trigger 
sensitivity over time (Martin & MacLeod, 2009; Martin et al., 2014). One factor that may 
contribute to migraineurs’ avoidance behaviors, and thus negatively affect self-efficacy, is fear of 
pain. 
Fear of Pain. The fear avoidance model (FAM) of pain was originally developed to 
describe the role of beliefs and behavioral responses in progression versus improvement of 
musculoskeletal pain following acute injury. The FAM posits that patients’ pain sensations and 
subsequent emotional reactions may become dysynchronous, leading to an exaggerated pain 
response (Lethem, Slade, Troup, & Bentley, 1983). According to the FAM (Lethem et al.), 
patients either confront or avoid their pain experiences as a function of their beliefs about 
harmfulness of pain sensations. Abstaining from activities putatively associated with pain is 
motivated by “fear of pain,” a perceived susceptibility to pain or reinjury resulting in avoidance 
of pain-related stimuli (Lethem et al.). Fear of pain leads to both cognitive and behavioral 
avoidance of pain experiences and activities that can persist well beyond the time needed for 
tissue healing. Prolonged avoidance leads to decreased social and physical activity, resulting in 
decreased exposure to pain, restricted behavioral coping repertoires, and physical decline 
stemming from deconditioning of the musculoskeletal system. A patient’s propensity for 
avoidance is influenced by a number of psychosocial factors including stressful life events, 
previous pain history, coping strategies, behavioral patterns, and anxiety sensitivity (Lethem et 
al.; Vlaeyen & Linton, 2000). These avoidance behaviors are negatively reinforcing (Lethem et 
al., 1983) but over time function to exacerbate pain (via deconditioning and increased sensitivity 
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to pain stimuli) and contribute to the development and maintenance of pain-related disability 
(Vlaeyen & Linton). Attention to patients’ fear of pain and resulting avoidance behaviors may 
inform effective interventions that promote confrontation of pain-related experiences (Bailey, 
Carleton, Vlaeyen, & Asmundson, 2010) and bolster self-efficacy.   
Though the FAM originally described pain-related behaviors resulting from 
musculoskeletal injury, some research aims to apply the model to headache disorders (Hursey & 
Jacks, 1992). Fear of pain and avoidance behaviors have long been studied in chronic pain 
conditions (Philips & Jahanshahi, 1985; Philips, 1987) and are particularly important in headache 
disorders given that patients often avoid triggers/stimuli associated with head pain. An early 
factor analytic study (Philips & Jahanshahi, 1986) examining pain behaviors in headache 
sufferers identified thirteen factors contributing to pain behavior, six of which were 
manifestations of avoidance behavior (and accounted for 42.6% of the total variance in pain 
behavior). Of the six factors, social avoidance accounted for the most variance (21.9%), such that 
headache sufferers avoided social activities more than other daily activities due to head pain 
(Philips & Jahanshahi). Social avoidance likely diminishes quality of life and contributes to 
headache-related disability, compromising headache-related self-efficacy and increasing risk for 
depression.  
Fear of pain is strongly associated with headache-related disability, even after controlling 
for pain severity, locus of control, self-efficacy, and emotional distress (Nash, Williams, 
Nicholson, & Trask, 2006). Building on this finding, Black, Fulwiler, and Smitherman (2015) 
explored fear of pain among young adults with headache and found that migraineurs endorsed 
greater fear of pain than non-headache controls and individuals with tension-type headache. This 
relationship remained after controlling for gender, depression, and anxiety. The same study also 
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found that fear of pain accounted for more variance in headache-related disability than the 
combination of anxiety, depression, and gender. Further, fear of pain mediated the relationship 
between pain severity and headache-related disability. Increases in fear of pain were also 
associated with more frequent and painful migraines. Though this study illuminated the role of 
fear of pain in headache-related disability, unexplained variance in disability remained.  
One variable that may account for additional variance in this relationship is self-efficacy, 
given the strong aforementioned association between disability and self-efficacy. Self-efficacy 
mediates the relationship between fear of pain and functional disability, but not depressive 
symptoms, in children with chronic headache disorders (Carpino et al., 2014). Increases in fear 
of pain predicted decreases in self-efficacy, which in turn predicted increased functional 
impairment. These findings suggests that self-efficacy may serve as a protective factor between 
fear of pain and resulting disability and that self-efficacy is more important for behavioral, rather 
than emotional, outcomes related to headache pain. Though a relationship between fear of pain 
and self-efficacy has been shown in children with chronic headache, no literature to date has 
explored this association in adult migraineurs, despite the fact that adults are far more likely to 
experience migraine than are children (Lipton et al., 2007). Taken together, the literature 
demonstrates potential importance of both fear of pain and self-efficacy as targets for treatment 
for reducing headache-related disability.  
Allodynia. A physiological aspect of migraine likely related to fear of pain is cutaneous 
allodynia. Cutaneous allodynia, the perception of non-noxious stimuli as painful on the skin 
(e.g., mild heat/cold, light touch or pressure; Burstein, Yarnitsky, Goor-Aryeh, Ransil, & Bajwa, 
2000), further contributes to one’s pain experience. Physiologically, allodynia results partially 
from central sensitization, a phenomenon resulting from lowered pain thresholds of central 
  11 
trigeminal neurons receiving input from the skin and dura. These lowered thresholds result in 
hypersensitivity to stimuli that would typically occasion little to no pain response (Burstein et al., 
2000). Allodynia in pain patients is differentiated into three types: thermal, dynamic mechanical, 
and static mechanical. Thermal allodynia occurs as a result of hypersensitivity to hot and cold 
stimuli. Dynamic mechanical allodynia, commonly termed brush allodynia, is the perception of 
brushing the skin as painful and is likely mediated by Aβ mechanoreceptive and capsaicin-
insensitive Aβ fibers. Finally, static mechanical allodynia is the perception of pressure on the 
skin as painful, a response mediated by Aδ nociceptive fibers (Lipton et al., 2008). A wide 
variety of pain patients experience allodynia (Jarrell & Arendt-Nielsen, 2016; Jensen & 
Finnerup, 2014), including migraineurs. The association of allodynia with migraine is likely due 
to similar physiological mechanisms stemming from sensitization of nociceptors and activation 
of meningeal perivascular pain fibers (Mathew, Kailasam, & Seifert, 2004). 
 Burstein and colleagues (2000) were the first to note the occurrence of cutaneous 
allodynia in migraineurs via quantitative sensory testing, following the identification of allodynia 
in animal models of migraine. Up to 79% of migraineurs may experience allodynia during 
migraine attacks (Burstein et al.). The relationship between migraine and allodynia is both 
temporal and site-specific, with pain sensitivity typically presenting ipsilateral to head pain 
(Mathew et al., 2004). Many migraineurs report allodynia symptoms at the peak of head pain, 
though allodynia may also occur between pain onset and peak intensity (Mathew et al.). 
Allodynia duration is most often confined to migraine attacks, though 20% of migraineurs 
experience persistent allodynia for 6 to 48 hours following migraine cessation (Mathew et al.). 
Further, allodynia is associated with a number of migraine characteristics. 
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Cutaneous allodynia is associated with increased migraine-related disability and is most 
prevalent in migraineurs aged 18 to 36 (Baykan et al., 2016; Kalita, Yadav, & Misra, 2009; 
Lipton et al., 2008). Allodynia appears to be a risk factor for migraine progression (Baykan et al.; 
Lipton et al.), as both migraine duration and frequency of attacks are positively associated with 
allodynia (Kalita et al.). Migraine aura is associated with a 3.5 fold increased risk for allodynia 
(Lipton et al., 2008), such that 70.5% of migraineurs with aura also experience allodynia during 
migraine attacks (Baykan et al.). Other migraine characteristics associated with allodynia include 
family history of headache, nausea, vomiting, phono- and photophobia, and prodromal 
symptoms (Baykan et al.). Allodynia may also be associated with hormonal changes in women, 
(Baykan et al.), though this association is less surprising given that women are disproportionately 
affected by migraine. Given the association of disabling migraine symptoms with allodynia, 
treatment regimens that reduce disability and enhance quality of life are of particular importance.  
Despite an array of efficacious pharmacological and behavioral migraine treatments, 
additional research is needed for understanding the role of allodynia in migraine treatment. 
Triptan medications, which act as 5-HT1B/1D receptor agonists, are common and effective acute 
treatments for migraine (Thorlund et al., 2014). However, treatment for migraineurs with 
allodynia is much less successful. A study comparing triptan therapy response in migraineurs 
with and without allodynia during attacks found that presence of allodynia predicted response to 
triptans, such that migraineurs who did not experience allodynia were more likely to be pain-free 
both one and four hours after treatment (Burstein, Collins, & Jakubowski, 2004). Additionally, 
Burstein and colleagues found that 83% of those without allodynia during migraine were pain-
free within 2 hours of sumatriptan treatment. Among those with allodynia symptoms, however, 
only 15% were pain-free if treatment was initiated after allodynia began, and 80% of these 
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individuals had a recurrence of pain within 8 to 16 hours of treatment. Conversely, 63% of those 
with allodynia were pain-free if sumatriptan administration preceded onset of allodynia 
symptoms. These findings suggest that allodynia moderates triptan response.  
Burstein and colleagues (2004) thus concluded that triptan treatment is highly effective 
for migraineurs in the absence of allodynia and may alleviate some pain for individuals with 
allodynia if pain is treated prior to allodynia onset (i.e., when head pain is first noticed). These 
findings suggest that individuals experiencing allodynia present with a narrow window of 
opportunity for alleviating migraine with triptans. Migraineurs with allodynia thus likely 
perceive triptan treatment as less efficacious, thereby reducing their ability to effect change and 
diminishing headache-related self-efficacy. As such, migraineurs who experience allodynia may 
benefit from behavioral interventions focused on increasing self-efficacy for managing migraine 
attacks and accompanying allodynia. However, additional research is warranted concerning the 
role of self-efficacy and other psychological factors in allodynia. 
Given the prevalence of psychological symptoms and disorders among migraineurs, those 
with allodynia often present with psychological comorbidities, though the literature is somewhat 
mixed. Allodynia uniquely contributes to the likelihood of depression among migraineurs 
(Louter et al., 2014; Louter et al., 2015). Individuals with allodynia also endorse more symptoms 
of anxiety and depression than those without allodynia, and symptom severity varies as a 
function of allodynia severity (d’Agostino, Francia, Licursi, & Cerbo, 2010; Kao et al., 2014). 
Notably, migraineurs who experience allodynia may experience more psychological difficulties 
than psychiatric patients. For instance, migraineurs with allodynia obtain significantly higher 
scores on measures of negative affect, lack of positive affect, and somatic arousal compared to 
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those without allodynia, non-headache controls, and both individuals with prior and current 
psychological diagnoses (Louter et al., 2014).  
By comparison, other studies have found no association between allodynia and 
psychological symptoms among migraineurs (Lovati et al., 2009; Lovati, D’Amico, Brambilla, 
Mariani, & Bussone, 2008). These discrepancies may result from differing methods of assessing 
allodynia and psychological symptoms. Studies that found an association between allodynia and 
psychological factors (Louter et al.; d’Agostino et al.; Kao et al., 2014) used a validated measure 
for assessing presence of allodynia, which provide severity cutoff scores. However, studies that 
found no association between allodynia and psychological factors (Lovati et al.; Lovati et al.) 
employed less rigorous methods of assessing allodynia symptoms, requiring experience of only 
one allodynia symptom for inclusion. Therefore, studies employing more rigorous methods of 
allodynia symptom assessment likely contained participants who experience allodynia during 
migraine. Further, studies finding significant relationships used multiple validated measures for 
assessing specific psychological symptoms, while those with null results used a single 
cumulative questionnaire for assessing broad psychopathology.  
Though self-efficacy is especially compromised in migraineurs with depression and 
anxiety, less is known about self-efficacy among migraineurs experiencing allodynia. Further, 
both allodynia and self-efficacy are influenced by migraine frequency and disability, though no 
literature to date has explored the relationship between self-efficacy and allodynia among 
migraineurs. Given that both migraine and allodynia are attributable to processes of central 
sensitization that occasion hypersensitivities to pain and resulting avoidance behaviors, increased 
fear of pain and decreased headache-related self-efficacy likely characterize allodynia in 
migraineurs. However, literature on this relationship is lacking. 
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Goals of the Present Study. 
Allodynia, fear of pain, and self-efficacy contribute to migraineurs’ pain experience and 
coping behaviors. Though literature to date has explored the relationship of each variable with a 
myriad of migraine characteristics and comorbidities, no integrative study exists. Principally, 
despite the role of allodynia in response to acute pharmacotherapies, the relationship between 
allodynia and self-efficacy remains unknown and unexplored. Allodynia likely exacerbates fear 
of pain and contributes to pain-related avoidance behaviors consistent with tenets of the FAM, 
likely decreasing adaptive coping and compromising self-efficacy. The current study thus aimed 
to explore the relationship between allodynia and self-efficacy among migraineurs and to assess 
whether fear of pain mediates this relationship. A potential clinical implication of the present 
study includes that migraineurs with allodynia may benefit from interventions targeting self-
efficacy as well as fear of pain (Bailey, Carleton, Vlaeyen, & Asmundson, 2010; Woods & 
Asmundson, 2008).   
Hypotheses 
Study Goal 1: To investigate whether allodynia is associated with self-efficacy in migraineurs. 
• Hypothesis 1a: Allodynia would be negatively associated with self-efficacy in 
migraineurs. 
• Hypothesis 1b: The association would remain after controlling for migraine frequency 
and disability. 
Study Goal 2: To investigate whether fear of pain mediates the association between allodynia 
and self-efficacy in migraineurs. 
  16 
• Hypothesis 2a: Fear of pain would mediate the association between allodynia and self-
efficacy in migraineurs, such that allodynia would predict increased fear of pain, which in 
turn would predict reduced self-efficacy. 
Hypothesis 2b: The association would remain after controlling for migraine frequency 
and disability in the mediation model 
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II. METHODS 
Participants 
The initial sample consisted of undergraduate students aged 18 years and older who 
completed computer-administered measures assessing headache symptoms, disability, allodynia, 
fear of pain, and self-efficacy among a larger battery of measures. Individuals meeting ICHD-3 
criteria for migraine with or without aura occurring on at least 2 days per month were retained 
for the present study. Individuals with or suspected of having another headache disorder 
(episodic or chronic tension type headache, posttraumatic headache, or cluster headache) were 
excluded. Other exclusion criteria included suspect effort, defined as participants completing the 
battery in the fastest 10% of completion time (i.e., <30 minutes). Assuming a medium effect size 
of f2 = .15, power of .80, and statistical significance of p < .05, a total sample size of 85 
participants was required. 
Materials 
Demographics Questionnaire. Participants completed a questionnaire to provide 
information about race, ethnicity, gender, and other demographic information. This measure can 
be found in Appendix A. 
Structured Diagnostic Interview for Headache-3 (SDIH-3). The SDIH-3 (Smitherman, 
Penzien, Rains, Nicholson, & Houle, 2015) is a modified version of the original computer-
administered and well-validated SDIH (Andrew, Penzien, Rains, Knowlton, & McAnulty, 1992), 
revised to comport with ICHD-3 diagnostic criteria. The SDIH-3 is a 17-item diagnostic 
interview that assesses for primary headache disorders by querying headache symptoms, 
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frequency, severity, and other diagnostic characteristics that aid in differential diagnosis. 
Additionally, the SDIH-3 includes appendix questions for assessing aura symptoms, cluster 
headache, medication overuse, and post-traumatic headache. This measure can be found in 
Appendix B. 
Headache Management Self-Efficacy (HMSE-25). The HMSE-25 (French et al., 2000) 
is a 25-item self-report measure that assesses headache-related self-efficacy, including 
individuals’ ability to prevent their headache episodes and manage head pain. Each item is 
scored using a 7-point Likert scale ranging from 1, “strongly disagree,” to 7, “strongly agree” 
with 9 reverse-scored items. HMSE-25 scores range from 25 to 175, with higher scores 
indicative of higher self-efficacy. The HMSE-25 exhibits excellent internal consistency (α = .90) 
and a positive correlation with the Headache-Specific Locus of Control Internal Subscale (r = 
.40), another measure of headache self-management (French et al.). This measure can be found 
in Appendix C. 
Headache Impact Test-6 (HIT-6). The HIT-6 (Kosinski et al., 2003) is a 6-item self-
report measure that assesses disability resulting from headache. Specifically, the HIT-6 assesses 
the impact of headache on psychological, cognitive, occupational, and social functioning over 
the past 4 weeks. The 6 items query responses on a 5-point Likert-type scale from “Never” to 
“Always” to assess frequency and severity of impairment. Scores range from 36 to 78, with 
scores of 60 and above indicating very severe impact of headache on functioning. Kosinski and 
colleagues found the HIT-6 to have good internal consistency, alternate forms, and test–retest 
reliability (0.89, 0.90, and 0.80, respectively), as well as high discriminate validity across 
headache diagnostic groups. This measure can be found in Appendix D. 
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Allodynia Symptom Checklist-12 (ASC-12). The ASC-12 (Lipton et al., 2008) is a 12-
item measure that queries cutaneous allodynia symptom frequency during headache. Each item 
represents a common context in which allodynia is experienced, rated as “does not apply to me” 
or occurring “never,” “rarely,” “less than 50% of the time,” or “> 50% of the time.” The first 
three responses receive a score of 0, symptoms that occur less than half the time receive a score 
of 1 point, and symptoms occurring half the time or more are scored 2 points. ASC-12 scores 
range from 0-24, with scores of 0-2 considered indicative of an absence of allodynia, scores of 3-
5 indicating mild allodynia, scores of 6-8 suggesting moderate allodynia, and scores of 9 or more 
indicating severe allodynia. The ASC-12 has a three-factor structure, such that it represents 
thermal, mechanical static, and mechanical dynamic allodynia. Finally, the ASC-12 demonstrates 
high sensitivity (84.8%) and low to moderate specificity (52.2%) compared to quantitative 
sensory testing (QST), the gold standard for assessing cutaneous allodynia. This measure can be 
found in Appendix E. 
Pain Anxiety Symptom Scale (PASS-20). The PASS-20 (McCracken & Dhingra, 2002) 
is an abbreviated version of the original 40-item PASS (McCracken, Zayfert, & Gross, 1992), 
which was developed to evaluate fear of pain across four domains: pain-related anxious 
physiological reactions, fearful cognitions, cognitive anxiety, and avoidance/escape behaviors. 
The PASS-20 retains good internal consistency, criterion validity, and construct validity from the 
original PASS. The subscales mirror the original PASS subscales with high intercorrelations 
(mean r = .95) and more modest correlations between nonmatching subscales (mean r = .57), 
supporting both good convergent and divergent validity. The PASS-20 items are rated on a 6-
point Likert scale ranging from 0, “never,” to 5, “always.” Possible scores range from 0 to 100, 
with higher scores indicative of greater fear of pain. This measure can be found in Appendix F. 
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Procedure  
The aforementioned measures were included as part of a larger online survey battery 
administered through SONA Systems via Qualtrics, used with undergraduate students enrolled in 
psychology courses. Students completed the online battery over three consecutive semesters and 
received modest course credit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
III.  
 
III.  RESULTS 
Statistical Analyses 
Descriptive statistics were summarized and distributions examined. Mahalanobis distance 
was used to determine and exclude multivariate outliers. Prior to conducting primary analyses, 
bivariate correlations between variables of interest were tested using Pearson correlation 
analyses. The primary analyses were then conducted in in three steps. First, a simple linear 
regression was conducted to assess the relationship between allodynia and self-efficacy among 
migraineurs. Second, a hierarchical linear regression was conducted to assess the relationship 
between allodynia and self-efficacy after controlling for migraine frequency and disability. 
Finally, the effect of allodynia on headache self-efficacy through fear of pain was assessed, both 
directly and indirectly using methods outlined by Hayes (2018). Bootstrapping procedures were 
used to estimate the 95% confidence interval of the indirect effect of allodynia on self-efficacy 
through fear of pain. 
Participant Demographics 
A total of 2003 students participated. Three-hundred twenty-four failed to complete the 
entire battery, 122 evidenced suspect effort by completing the battery in less than 30 minutes, 
and 3 were under 18 years old. These participants were excluded from analyses. Additional 
exclusions included participants who did not complete headache-specific items necessary to 
assign headache diagnosis (n = 87), denied headache (n = 357), endorsed symptoms consistent 
with probable migraine (n = 350) or probable TTH (n = 272), or reported symptoms consistent 
with episodic TTH (n = 197), chronic TTH (n = 10), cluster headache (n = 20), less than 2 
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migraine days per month (n = 10), or headache attributable to head injury (n = 97). One 
participant did not complete the Allodynia Symptom Checklist-12 and was excluded from 
analyses. 
Table 1 presents demographic characteristics of the retained sample. The final sample 
consisted of 147 college students (87.80% female) with a mean age of 18.98 years old (SD = 
2.39). The majority of the sample was Caucasian (86.4%); 11.6% were African American, 1.4% 
identified as multiracial, and 0.7% were Hispanic/Latina. Regarding headache diagnosis, of the 
147 migraineurs retained, 56 (38.1%) met diagnostic criteria for episodic migraine without aura, 
49 (33.3%) met diagnostic criteria for episodic migraine with aura, and 42 (28.6%) met criteria 
for chronic migraine. On average, participants reported experiencing nearly ten headache days 
per month, with severe headache-related disability and mild levels of allodynia. Participants’ 
mean headache management self-efficacy scores were moderate, and their mean fear of pain 
scores were elevated. Regarding allodynia, 44.2% of the sample reported experiencing no 
allodynia symptoms, while 55.8% reported experiencing some level of allodynia symptoms. 
Data Analytic Assumptions 
 Histograms and descriptive statistics (i.e., kurtosis, skewness) were used to assess 
analytic assumptions for variables of interest (ASC-12, HMSE-25, PASS-20, and HIT-6) and 
found to be satisfactory. All participants were assessed for multivariate outliers on total scores of 
interest by Mahalanobis distance prior to performing statistical analyses; six multivariate outliers 
were found using a conservative p < .001 cutoff and were excluded from all analyses. Twenty-
two percent of the remaining 147 participants had missing total scores due to missing values 
(total missing data = 0.48%). Missing values were imputed using mean substitution by group 
(i.e. with and without allodynia).  
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Correlations Among Variables of Interest 
 Significant correlations were found between each of the variables. Table 2 presents 
correlations among allodynia and associated headache variables. Allodynia showed a small 
positive association with fear of pain and headache-related disability (both rs = .21). Headache-
related disability showed a small positive relationship with fear of pain and a moderate-to-large 
positive relationship with headache frequency and severity. Finally, fear of pain showed a small 
positive relationship with both headache frequency and severity. Differences between 
migraineurs with and without allodynia are presented in Table 3, revealing those with allodynia 
reporting significantly greater fear of pain than those without (M = 37.00 vs. 31.81, 
respectively). Those with and without allodynia did not differ on headache-related disability or 
self-efficacy.   
Regression Analyses 
 First, a simple linear regression was performed to “predict” headache-related self-
efficacy based on allodynia among migraineurs. A significant negative relationship between 
allodynia and self-efficacy emerged (R2 = .03, p = .049), such that for each one-point increase on 
the ASC-12, participants’ HMSE-25 scores decreased .93 points. Next, a hierarchical multiple 
regression was performed to “predict” headache-related self-efficacy based on allodynia after 
adding migraine frequency and disability into the model. Complete results of the hierarchical 
multiple regression are presented in Table 4. Block 1, which included migraine frequency and 
disability, was significant (R2 = .16, p < .001), with headache variables accounting for 16% of 
the variance in headache-related self-efficacy. Block 2, which incorporated allodynia, was not 
significant (∆R2 = .01, p = .21), as allodynia accounted for only 1% of the change in variance in 
headache-related self-efficacy. The overall model remained significant (p < .001), although 
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headache-related disability was the only significant predictor of self-efficacy in the final model 
(β = -.393, p < .001), indicating that as disability increases, self-efficacy decreases.  
Mediation Analysis 
 Using the PROCESS macro for SPSS (Hayes, 2018), the effect of allodynia on self-
efficacy was assessed directly and indirectly through fear of pain. Bootstrapping procedures were 
used to estimate the 95% confidence interval of the indirect effect of allodynia on self-efficacy 
through fear of pain using 5,000 bootstrapped samples. Mediation results are presented in Figure 
1. The total effect of allodynia on self-efficacy was -.93, p = .049, as was expected given it 
replicates results from the aforementioned regression, indicating that self-efficacy is reduced for 
migraineurs with allodynia. For every one-point increase on ASC-12 scores, HMSE-25 scores 
decrease by nearly one point on average. Allodynia was positively associated with fear of pain 
(path a = 0.99, p < .01), but fear of pain was not associated with self-efficacy (path b = .01, p = 
.93). The direct effect of allodynia on self-efficacy was -.94, p = .05, indicating that holding fear 
of pain constant does not result in statistically significant changes in self-efficacy as a result of 
allodynia, although this effect fell just shy of statistical significance. Finally, the indirect effect 
of allodynia on self-efficacy through fear of pain was assessed in the mediation model. The 
indirect effect of allodynia on self-efficacy through fear of pain was .01, 95% CI(-.27, .22), 
which is not statistically significant given that the confidence interval contains zero. Therefore, 
fear of pain does not appear to mediate the relationship between allodynia and self-efficacy 
among migraineurs.  
Supplementary Analyses 
 Supplementary analyses were performed to explore whether null results from the 
mediation model might be attributable to collapsing episodic and migraineurs together. 
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Differences in allodynia scores were analyzed between migraine diagnostic groups (i.e., 
migraine, migraine with aura, chronic migraine) by performing a one-way analysis of variance 
(ANOVA). The ANOVA yielded non-significant results (F[2, 144] = .87, p = .420), indicating 
that allodynia scores were not statistically different between diagnostic groups. Results from this 
analysis are presented in Table 5.
1 
IV.  
V.  
VI. IV.  DISCUSSION 
The impact of allodynia on pain conditions is often considered throughout headache and 
chronic pain literature, though little research to date has explored psychological correlates of 
allodynia. The present study sought to examine the relationship between allodynia and self-
efficacy among migraineurs and the possible influence of fear of pain on the hypothesized 
relationship.  
Relationships Between Allodynia and Self-Efficacy  
Consistent with Hypothesis 1a, allodynia and self-efficacy showed a small but significant 
negative relationship, such that as allodynia severity increased, migraineurs’ self-efficacy 
decreased. This is the first study to our knowledge to demonstrate a relationship between 
allodynia and self-efficacy, either within headache literature or pain literature more broadly. 
Prior research demonstrated that migraineurs with allodynia present with a narrow window for 
relieving head pain with triptan treatment (Burstein, Collins, & Jakubowski, 2004), suggesting 
counseling in medication adherence and alternative methods of treatment, such as behavioral 
self-management, may be promising interventions for such patients. Chronic disease literature 
suggests that self-management skills are superior to information-only education and improve 
functional outcomes (Bodenheimer, Lorig, Holman, & Grumbach, 2002). Further, self-efficacy is 
a critical component of self-management among chronic pain conditions broadly (Bodenheimer 
et al.; Marks, Allegrante, & Lorig, 2005), indicating that enhancing and promoting self-efficacy 
results in improvements in disability and disease prognosis more generally.  
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Efficacy of non-pharmacological migraine management is well established for improving 
migraine frequency and disability (Rains, Penzien, McCrory, & Gray, 2005; Nicholson, Nash, & 
Andrasik, 2005). More recent research (Seng & Holroyd, 2010) exploring the impact of 
treatment expectancies on headache outcomes found that the addition of behavioral migraine 
management to pharmacotherapy yielded greater increases in headache-related self-efficacy than 
pharmacotherapy alone. Seng and Holroyd also demonstrated that behavioral management 
improved internal locus of control and decreased chance locus of control, regardless of 
pharmacotherapy condition (i.e., beta blocker or placebo). Early work on biofeedback suggested 
that resulting improvements in TTH derived not from physiological changes, but from cognitive 
changes stemming from perceptions of success and increases in self-efficacy and internal locus 
of control (Holroyd et al., 1984). Further evidence suggests that self-efficacy itself is the 
mechanism of change in cognitive behavioral interventions. Specifically, self-efficacy at two 
months mediated the relationship between stress management and disability outcomes at eight 
months among individuals with TTH (Holroyd, Labus, & Carlson, 2009), underscoring the 
mechanistic role of psychological processes in self-management approaches to treatment. The 
present negative relationship between allodynia and self-efficacy in migraineurs suggests that 
self-efficacy’s influence on functional outcomes and treatment response is a variable worth 
investigating among patients with allodynia. 
To the extent allodynia is associated with reduced headache self-efficacy, migraineurs 
with allodynia (especially those responding poorly to pharmacotherapy) may benefit from the 
addition of behavioral migraine management and corresponding improvements in self-efficacy. 
Because low self-efficacy is associated with high external locus of control (French et al., 2000), 
migraineurs with allodynia may in fact view themselves as poor candidates for behavioral 
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management (Seng & Holroyd, 2010), given that they believe migraine is influenced by factors 
other than their own behavior. In fact, though, patients with high external locus of control exhibit 
greater improvements in self-efficacy following behavioral migraine management than those 
with a high internal locus of control (Seng & Holroyd). Though no studies to our knowledge 
have evaluated the efficacy of behavioral migraine interventions for individuals with allodynia, 
work in this area holds promise for increasing available treatment options to this challenging 
subgroup of migraine patients.  
Contrary to Hypothesis 1b, however, the observed relationship between allodynia and 
self-efficacy proved non-significant after accounting for migraine frequency and disability. Only 
17% of total variance in self-efficacy was accounted for in the model—most of which was 
attributable to disability—leaving a large proportion of variance in self-efficacy unexplained. 
Perhaps anxiety sensitivity and medication overuse would account for additional variance in self-
efficacy among migraineurs with allodynia. Anxiety sensitivity (AS) is characterized by 
hypersensitivity to physiological sensations and misinterpretation of these sensations as 
dangerous (Reiss, 1991). Applied to headache, AS may present as misinterpretation of sensations 
as indicative of headache onset, leading to subsequent avoidance of activities occurring during 
misinterpretation (Nicholson et al., 2007). Evidence shows that AS influences escape and 
avoidance behaviors in headache patients (Norton & Asmundson, 2004) and predicts sensitivity 
to headache triggers (Smitherman, Davis, Walters, Young, & Houle, 2015). Taken together, 
these findings suggest that migraineurs with high AS avoid pain-related stimuli, which likely 
increases sensitivity to pain. In an attempt to prevent or attenuate head pain, such patients may 
unnecessarily utilize acute headache medications, resulting in medication overuse. Among 
headache patients, medication overuse headache (MOH) not only impacts attack frequency and 
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disability (Peck, Roland, & Smitherman, 2018), but also likely develops in part from central 
sensitization (De Felice, Ossipov, & Porreca, 2011), thus increasing risk for allodynia. Though 
AS and medication overuse were not considered in the present study, they may account for some 
unexplained variance in self-efficacy among migraineurs with allodynia. 
Mediation Analysis 
In accordance with hypotheses, allodynia and self-efficacy were negatively associated 
with one another, presenting an effect to be mediated. Contrary to Hypothesis 2a, however, the 
mediation analysis showed that fear of pain does not serve a mediating role between allodynia 
and self-efficacy in migraineurs. However, a positive relationship between allodynia and fear of 
pain was found, indicating that FOP increases with allodynia symptom severity. Given that 
allodynia results from central sensitization and is characterized by hypersensitivity to non-
painful stimuli, migraineurs experiencing allodynia may engage in more pain-avoidant 
behaviors, consistent with the FAM, than those without allodynia. As mentioned above, one such 
maladaptive avoidance behavior includes taking acute medication prematurely, leading to 
medication misuse and possibly MOH as it confers increased risk for progression of headache 
frequency. Indeed, patients meeting diagnostic criteria for MOH are increasingly likely to engage 
in pain avoidant behaviors compared to those without MOH (Peck, Roland, & Smitherman, 
2018). Though the exact mechanisms underlying MOH are unknown, central sensitization is 
likely implicated (De Felice, Ossipov, & Porreca, 2011), suggesting that MOH and allodynia 
share physiological underpinnings that likely contribute to maladaptive avoidance and escape 
behaviors characterizing fear of pain. Moreover, repeated administration of pharmacotherapy in 
the absence of pain relief likely fosters reduced self-efficacy for headache self-management and 
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increased reliance on medication. Should the proposed cycle exist, decreased self-efficacy may 
maintain medication overuse over time.  
Perhaps allodynia and fear of pain are better considered in the context of other pain-
related variables, such as medication overuse, rather than self-efficacy given that no significant 
bivariate correlation was found between fear of pain and self-efficacy. This particular finding is 
inconsistent with results found in the broader chronic pain literature, which indicate that 
increases in self-efficacy are associated with reductions in fear of pain (Perry & Francis, 2013; 
Woby et al., 2007). Further, findings suggest that self-efficacy mediates the relationship between 
fear of pain and disability in a sample of adult chronic pain participants (Perry & Francis, 2013), 
which included a small percentage of chronic migraineurs. However, participants in these studies 
had complex pain histories and were on average 20 years older than the participants in the 
present study, making generalizations and comparisons difficult. Further, participants in the 
aforementioned studies endorsed markedly lower self-efficacy than the present sample, which 
may account for disparate findings. 
Finally, considering the positive association between allodynia and fear of pain found in 
the present study, the predicted mediation effect may present when considering the role of FOP 
in the relationship between allodynia and disability, rather than self-efficacy. The positive 
relationship between allodynia and disability is well established (Baykan et al., 2016; Lipton et 
al., 2008), and recent research exploring psychological mediators of headache variables show 
that both self-efficacy (Peck & Smitherman, 2015) and fear of pain (Black, Fulwiler, & 
Smitherman, 2015) mediate the relationship between headache severity and disability. Allodynia 
is closely related to migraine severity, such that migraineurs with more severe allodynia 
experience more severe head pain (Jakubowski, Silberstein, Ashkenazi, & Burstein, 2005). The 
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close relationship between allodynia and pain severity suggests that exploring the mediating role 
of psychological variables, such as fear of pain, on the relationship between allodynia and 
disability is worth exploring in future research. The present study explored self-efficacy, rather 
than disability, as a dependent variable because evidence suggests that self-efficacy is both an 
important mechanism of change and treatment outcomes in migraine management. 
Supplementary Analysis 
Prior research demonstrates that patients with aura and chronic migraine experience more 
severe allodynia than those with episodic migraine and without aura (Lipton et al., 2008). To test 
whether the predicted mediation effect was attributable to collapsing episodic and chronic 
migraineurs, supplemental analyses were conducted exploring differences in allodynia as a 
function of headache diagnosis. Contrary to prior findings, the current study found no significant 
differences in allodynia between participants with migraine, migraine with aura, and chronic 
migraine diagnoses. However, allodynia severity in the current sample was, on average, 
somewhat lower than that from prior studies (Bigal et al., 2008), though many studies simply 
report the presence versus absence of allodynia rather than severity ratings. 
Limitations and Future Directions 
The present study is strengthened by adherence to ICHD-3 diagnostic criteria; use of 
validated measures of headache disability, headache-related self-efficacy, fear of pain, and 
allodynia; and a sample comprised of young adults with frequent migraine. However, some 
limitations exist and should be considered when interpreting the study’s conclusions. First, the 
study relied on retrospective report concerning headache symptomatology and associated 
psychological variables. While the computer-administered SDIH-3 adheres to ICHD-3 diagnostic 
criteria, interview-based diagnoses would strengthen confidence in validity of the current study. 
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Similarly, quantitative sensory testing (QST) is the gold standard method for assessing allodynia. 
While the ASC-12 is a well-validated self-report measure of allodynia symptoms, the use of QST 
evaluative methods would provide more objective data concerning allodynia symptoms 
experienced during and between migraine attacks. Second, given that the sample primarily 
consisted of non-treatment seeking, young undergraduate students, results may not generalize to 
clinical populations or older adults given that treatment seeking samples present with both more 
severe pain quality and allodynia symptoms. However, the current sample endorsed nearly ten 
headache days per month, a strikingly high frequency for an undergraduate, non-treatment 
seeking sample. Further, given that allodynia is associated with migraine chronicity (Bayken et 
al., 2016; Lipton et al, 2008), the current sample may not present with highly complex headache 
histories, though they reported high migraine frequency and marked disability resulting from 
head pain. Young adults in their mid-twenties to early thirties may present with more extensive 
headache and allodynia histories, given that allodynia prevalence is highest among adults aged 
18-36 (Baykan et al.). However, mean age of the present sample falls within this age range. 
Though it is possible that the predicted mediation effect may not prove significant if the study is 
underpowered, the present study utilized a sample nearly twice that required based on an a priori 
power analysis. Finally, the present study employed cross-sectional methods and as such, 
associations should be recognized as correlational rather than causal given uncertainty regarding 
temporal relationships among variables.  
Future research should utilize treatment-seeking migraineurs and physiologically based 
methods for assessing allodynia, such as QST. Additionally, future research should endeavor to 
understand the relationship between allodynia and self-efficacy through other pain-related 
variables, such as medication overuse, or attend to outcomes variables more consistently linked 
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to allodynia such as disability or headache frequency (Baykan et al., 2016; Lipton et al., 2008). 
The significant negative association between allodynia and self-efficacy suggests that self-
efficacy may be an important target for and mechanism of change in behavioral interventions for 
patients with allodynia, although this awaits empirical verification. Studies examining the utility 
of behavioral interventions broadly, and on self-efficacy specifically, among migraineurs with 
allodynia may highlight important clinical considerations in treating these patients. 
Allodynia may also show relationships with variables such as fear of pain and medication 
overuse due to disproportionately high rates of avoidance behaviors, consistent with the FAM. 
Exploring the topography of avoidance behaviors among migraineurs with and without allodynia 
could expose meaningful differences in pain-related avoidance behaviors among patients with 
allodynia. Such differences could inform targeted behavioral interventions for allodynia. 
Additionally, given the shared physiological underpinnings of migraine, allodynia, and 
medication overuse, psychological variables leading to central sensitization, such as chronic or 
prolonged stress, may be relevant clinically. Finally, literature to date is mixed regarding 
psychological correlates of allodynia, such as depression and anxiety, likely due to varying 
methodological approaches. More conclusive research in this area is needed to improve 
understanding of psychological comorbidities among migraineurs with allodynia. 
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Table 1. Demographic Characteristics of the Sample 
 
 
  
 
Variable       % or Mean (SD) 
Gender (% Female)  87.8 
       
Mean Age (SD)   18.98 (2.39) 
       
Race (% Caucasian)  86.4 
       
Episodic Migraine % (w/o aura) 38.1 
       
Episodic Migraine % (w/ aura) 
 
Chronic Migraine % 
 
Mean Headache Days/Month (SD) 
 
33.3 
 
28.6 
 
9.90 (5.85) 
       
Employment (% Unemployed) 70.7 
       
Income (% <$10,000)  36.1 
       
Religion (% Protestant Christian) 40.1 
       
Relationship (% Not In Relationship) 60.5 
       
Father's Education (% ≥ bachelor’s degree) 55.1 
       
Mother’s Education (% ≥ bachelor’s degree) 65.9 
       
Mean Headache Severity (SD) 
 
Mean ASC-12 Score (SD) 
6.02 (1.50) 
 
3.69 (3.46) 
       
Mean HMSE Score (SD)  101.18 (19.72) 
      
Mean HIT-6 Score (SD) 
 
Mean PASS-20 Score (SD) 
     
60.76 (6.68) 
 
34.70 (15.72) 
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Table 2. Pearson correlations among allodynia and associated headache variables 
 
Measure 1 2 3 4 
1. ASC-12     
2. HIT-6 .18*    
3. PASS-20 .22** .22**   
4. Frequency .14 .46** .25**  
5. Severity .50** .49** .17* .25** 
* p < .05 
** p < .01 
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Table 3. Group differences between migraineurs with and without allodynia. 
 
 Allodynia group 
mean (SD) 
No allodynia group 
mean (SD) 
t-tests 
HIT-6 61.60  
(6.29) 
59.71  
(7.05) 
t(145) = -1.71 
PASS-20 37.00 
(17.07) 
31.81  
(13.40) 
t(145) = -2.01* 
HMSE-25 99.79  
(17.57) 
102.93  
(22.15) 
t(145) = .96 
* p = .04 
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Table 4. Regression Analysis Results  
 
  Adjusted 
   
Beta 
 
95% CI for 
Beta 
 
R2 
 
∆R2 
P-
value 
of ∆R2 
P-
value 
of 
Model 
Block 1    15.5%   <.001 
Frequency  -.002 -.59 –  .58     
HIT-6  -.393 -1.67 – -.65     
Block 2    16.4% 1% .214 <.001 
ASC-12  -.097 -1.43 –  .32     
CI = confidence interval 
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Table 5. One-way ANOVA comparing allodynia across migraine diagnoses 
 
 Sum of Squares df 
Mean 
Square F Sig. 
Between Groups 20.912 2 10.456 .872 .420 
Within Groups 1726.313 144 11.988   
Total 1747.224 146    
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Figure 1. Path coefficients for simple mediation analysis on self-efficacy 
 
  
 
Note: c denotes the total effect while c’ denotes the effect of allodynia on HMSE when fear of pain is not 
included as a mediator.  
 
* p < .05 
** p < .01 
 
 
 
Fear of Pain 
 
Allodynia 
Headache 
Management 
c’ = -.94; SE = .48 
CI: -1.89 – .01 
c = -.93*; SE = .47 
CI: -1.85 – -.01 
a = 0.99**; SE = .37 
CI: .27 – 1.72 
b = -.01; SE = .11 
CI: -.20 – .22  
a
 
c
 
S
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Please answer the following questions. 
 
1. What is your biological sex?    
   0 = Male      
   1 = Female 
2. How old are you? ____ (Ranges from 18 to 64) 
3. What is your marital status? 
 0 = Never married   3 = Separated    
 1 = Married    4 = Widowed 
 2 = Divorced/Annulled  5 = Not married, but living with partner 
4. Who do you currently live with? Check all that apply. 
 0 = Alone    3 = Other relative 
 1 = Spouse or romantic partner 4 = Friend or roommate 
 2 = Children (under age 18)   
5. What is your highest education level completed? 
 0 = Elementary (8th grade or less) 4 = Bachelor’s Degree  
 1 = Some High School  5 = Master’s Degree 
 2 = High School Diploma  6 = Doctoral or professional degree (PhD, MD, etc.) 
 3 = Some College    
6. What best describes your current employment status? 
  0 = Unemployed   3 = Full-time (40 hours per week or more)  
 1 = Home Maker     
 2 = Part-Time 
7. What best describes your total household income (before taxes)? 
 0 = Less than 10,000   3 = $31,000 to $50,000   
 1 = $10,000 to $20,000  4 = $51,000 to $100,000  
 2 = $21,000 to $30,000  5 = Greater than $100,000 
8. Do you describe yourself as a Hispanic or Latino? 
 0 = No      
 1 = Yes   
9. What is your race? 
 0 = White    3 = Native American, Alaskan Native 
 1 = Black/African American  4 = Asian or Pacific Islander 
 2 = Asian    5 = Native Hawaiian or Other Pacific Islander 
      6 = Multiracial (list numbers ____& ____& ___) 
10. What is your religious affiliation? 
1. Protestant Christian 5. Muslim 
2. Roman Catholic  6. Hindu 
3. Evangelical Christian 7. Buddhist 
4. Jewish   8. Other: ______________________ 
9. I am not religious 
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APPENDIX B: STRUCTURED DIAGNOSTIC INTERVIEW FOR HEADACHE – 3 (BRIEF 
VERSION (SDIH-3) 
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APPENDIX C: HEADACHE MANAGEMENT SELF-EFFICACY SCALE – 25 (HMSE-25) 
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Instructions: You will find below a number of statements related to headaches. Please read each 
statement carefully and indicate how much you agree or disagree with the statement by circling a 
number next to it.  Use the following scale as a guide: 
 
Strongly 
Disagree 
Moderately 
Disagree 
Slightly 
Disagree 
Neither 
Agree or 
Disagree 
Slightly 
Agree 
Moderately 
Agree 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
1)  
I can keep even a bad headache from disrupting my day by 
changing the way I respond to the pain. 
1     2     3     4     5     6      7 
2) * 
When I’m in some situations, nothing I do will prevent 
headaches.* 
1     2     3     4     5     6      7 
3)  
I can reduce the intensity of a headache by relaxing. 1     2     3     4     5     6      7 
4)  
There are things I can do to reduce headache pain. 1     2     3     4     5     6      7 
5)  
I can prevent headaches by recognizing headache triggers. 1     2     3     4     5     6      7 
6)  
Once I have a headache there is nothing I can do to control 
it.* 
1     2     3     4     5     6      7 
7)  
When I’m tense, I can prevent headaches by controlling the 
tension. 
1     2     3     4     5     6      7 
8)  
Nothing I do reduces the pain of a headache.* 1     2     3     4     5     6      7 
9)  
If I do certain things every day, I can reduce the number of 
headaches I will have. 
1     2     3     4     5     6      7 
10)  
If I can catch a headache before it begins I often can stop 
it. 
1     2     3     4     5     6      7 
 
Please complete reverse side 
 
Strongly 
Disagree 
Moderately 
Disagree 
Slightly 
Disagree 
Neither 
Agree or 
Disagree 
Slightly 
Agree 
Moderately 
Agree 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
11)  
Nothing I do will keep a mild headache from turning into a 
bad headache.* 
1     2     3     4     5     6      7 
12)  
I can prevent  headaches by changing how I respond to 
stress. 
1     2     3     4     5     6      7 
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13)  
I can do things to control how much my headaches interfere 
with my life. 
1     2     3     4     5     6      7 
14)  
I cannot control the tension that causes my headaches.* 1     2     3     4     5     6      7 
15)  
I can do things that will control how long a headache lasts. 1     2     3     4     5     6      7 
16)  
Nothing I do will keep a bad headache from disrupting my 
day.* 
1     2     3     4     5     6      7 
17)  
When I’m not under a lot of stress I can prevent many 
headaches. 
1     2     3     4     5     6      7 
18)  
When I sense a headache is coming, there is nothing I can 
do to stop it. * 
1     2     3     4     5     6      7 
19)  
I can keep a mild headache from disrupting my day by 
changing the way I respond to the pain. 
1     2     3     4     5     6      7 
20)  
If I am under a lot of stress there is nothing I can do to 
prevent headaches.* 
1     2     3     4     5     6      7 
21)  
I can do things that make a headache seem not so bad. 1     2     3     4     5     6      7 
22)  
There are things I can do to prevent headaches. 1     2     3     4     5     6      7 
23)  
If I am upset there is nothing I can do to control the pain of 
a headache.*  
1     2     3     4     5     6      7 
24)  
I can control the intensity of headache pain. 1     2     3     4     5     6      7 
25)  
I can do things to cope with my headaches. 1     2     3     4     5     6      7 
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APPENDIX E: ALLODYNIA SYMPTOM CHECKLIST – 12 (ASC-12) 
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Allodynia Symptom Checklist – 12 (ASC-12) 
 
Scoring: 
None  0-2 
Mild  3-5 
Moderate 6-8 
Severe  9 or more 
  
How often do you 
experience increased 
pain or an unpleasant 
sensation on your skin 
during your most 
severe type of 
headache when you 
engage in each of the 
following? 
Does not 
apply to 
me (0) 
Never (0) Rarely (0) Less than 
half of 
the time 
(1) 
Half of 
the 
time or 
more 
(2) 
Combing your hair      
Pulling your hair back 
(e.g., ponytail) 
     
Shaving your face      
Wearing eyeglasses      
Wearing contact lenses      
Wearing earrings      
Wearing a necklace      
Wearing tight clothing      
Taking a shower (when 
shower water hits your 
face) 
     
Resting your face or 
head on a pillow 
     
Exposure to heat (e.g., 
cooking, washing your 
face with hot water) 
     
Exposure to cold (e.g., 
using an ice pack, 
washing your face with 
cold water) 
     
Total score      
Sum of total scores  
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APPENDIX F: PAIN ANXIETY SYMPTOM SCALE – 20 (PASS-20) 
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PASS-20 
Please read each item carefully, and then rate how often each statement applies to your life 
using the following scale: 
0               1                  2                    3               4              5 
            Never                Always 
 
1) I can’t think straight when in pain. _____ 
2) During painful episodes it is difficult for me to think of anything besides the pain ____ 
3) When I hurt I think about pain constantly _____ 
4) I find it hard to concentrate when I hurt _____ 
5) I worry when I am in pain _____ 
6) I go immediately to bed when I feel severe pain _____ 
7) I will stop any activity as soon as I sense pain coming on _____ 
8) As soon as pain comes on I take medication to reduce it _____ 
9) I avoid important activities when I hurt _____ 
10)  I try to avoid activities that cause pain _____ 
11)  I think that if my pain gets too severe, it will never decrease _____ 
12)  When I feel pain I am afraid that something terrible will happen _____ 
13)  When I feel pain I think that I might be seriously ill _____ 
14)  Pain sensations are terrifying _____ 
15)  When pain comes on strong I think that I might become paralyzed or more disabled ____ 
16)  I begin trembling when engaged in an activity that increases pain _____ 
17)  Pain seems to cause my heart to pound or race _____ 
18)  When I sense pain I feel dizzy or faint _____ 
19)  Pain makes me nauseous _____ 
20)  I find it difficult to calm my body down after periods of pain _____ 
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Psychopharmacology Research Laboratory      
Advisor: Kenneth Sufka, Ph.D. 
 
Summer Research Intern, Center of Biomedical Research Excellence 2015 
Grant Number: NIGMS P20GM104932 
Supervisor: Michael Repka, D.D.S., Ph.D. 
 
PUBLICATIONS & PRESENTATIONS 
Journal Articles 
Davis-Martin, R. E., Polk, A. N., & Smitherman, T. A. (2017). Alcohol use as a 
comorbidity and precipitant of primary headache: Review and meta-analysis. Current 
Pain and Headache Reports, 21(42). DOI: https://doi.org/10.1007/s11916-017-0642-8 
 
Tiwari, R., Polk, A., Patil, H., Ye, X., Pimparade, M., Repka, M. (2015). Rat palatability 
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study for taste assessment of caffeine citrate formulation prepared via hot-melt 
extrusion technology. AAPS PharmSciTech. Advanced online publication. DOI: 
10.1208/s12249-015-0447-1  
Oral Presentations 
Polk, A. & Smitherman, T. (2019, April). Allodynia, stress, and disability in migraineurs: 
A mediation analysis. Presented at the 2019 UM Conference on Psychological Science, 
Oxford, MS.  
 
Polk, A. (2018, April). What’s your path? M.A., Ph.D., Psy.D. Presented at the 2018 UM 
Conference on Psychological Science, Oxford, MS. 
 
Polk, A., Johnson, Y., & Smitherman, T. (2017, September). Comparing the effects of 
cognitive & social stress in individuals with headache. In M. Perry (Chair), The age of 
anxiety: Exploring and assessing anxiety and its' problematic health 
correlates. Presented at the Mississippi Psychological Association's 68th Annual 
Convention; Biloxi, MS.  
 
Sharpe, K. M., Polk, A. N., & Smitherman, T. A. (2017, April) Perceptions of headache 
triggerpPotency. Presented at the 2017 UM Conference on Psychological Science, 
Oxford, MS. 
 
Poster Presentations 
Wittig, C., Cochran, S., Mullen, C., Polk, A., & Smitherman, T. (2019, April). 
Psychological correlates of allodynia. Presented at the 2019 UM Conference on 
Psychological Science, Oxford, MS. 
 
Sharpe, K. M., Crow, M. K., Polk, A. N., & Smitherman, T. A. (2016, April). Trigger 
stimuli in young adults with migraine and tension-type headache. Presented at the 2016 
UM Conference on Psychological Science, Oxford, MS. 
 
ATTENDED WORKSHOPS & TRAININGS 
Hayes, A. F. (2018, October). Introduction to Mediation, Moderation, and Conditional Process 
Analysis. Presented at the University of Mississippi. 
 
PROFESSIONAL MEMBERSHIPS 
Student Member, Association for Behavioral and Cognitive Therapies (ABCT) 
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Student Member, Mississippi Psychological Association (MPA) 
Member, Women in Behavior Analysis (WIBA) 
 
TEACHING EXPERIENCE 
Instructor of Record        July 2018 
PSY 410, Health Psychology        
 
Graduate Teaching Assistant        
PSY 309, Learning        2018-present 
PSY 201, General Psychology       2016-2018 
 
Undergraduate Teaching Assistant      2015-2016 
PSY 341, Multicultural Psychology 
 
AWARDS & ACHIEVEMENTS 
Graduate Honors Fellowship       2016-present 
Chancellor’s Honor Roll, University of Mississippi    2012-2016 
Phi Kappa Phi Honor Society 
Phi Beta Kappa Honor Society 
Provost Scholar, University of Mississippi 
 
PROFESSIONAL EXPERIENCE 
Administrative Assistant to the Clinical Training Program July 2018-present 
DCT & Supervisor: Todd Smitherman, Ph.D. 
Assisted with incoming graduate student orientation; planned, coordinated, and executed 
clinical and experimental programs’ Interview Weekend; assisted with APA self-study; 
coordinated details of faculty candidate interviews 
 
LEADERSHIP EXPERIENCE & SERVICE 
Chancellor’s Standing Committees   August 2018-present 
University of Mississippi    
LGBTQ Affairs 
Artist Series 
 
Graduate Student Faculty Representative   August 2018-present 
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University of Mississippi Psychology Department  
  
Graduate Student Council      May 2018-present 
Director of Social & Philanthropic Affairs   
 University of Mississippi 
 
Chair’s Graduate Student Advisory Council     2016-2017 
University of Mississippi Psychology Department 
 
Judicial Board         2015-2016 
University of Mississippi 
 
RELEVANT COURSEWORK 
ACT Seminar         Spring 2019 
Instructor: Kelly Wilson, Ph.D. 
 
Seminar on College Teaching       Spring 2018 
Instructor: Kenneth Sufka, Ph.D. 
 
Evidence Based Treatments Seminar       Fall 2017 
Instructor: John Young, Ph.D. 
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